Fresenius SE & Co. (OTCMKTS:FSNUY) Hits New 1-Year Low – What’s Next?

Posted by Stephan Jacobs on May 5th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares hit a new 52-week low on Tuesday . The company traded as low as $11.54 and last traded at $11.54, with a volume of 25412 shares trading hands. The stock had previously closed at $11.98.

Analysts Set New Price Targets

FSNUY has been the subject of a number of research reports. Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research report on Tuesday, February 3rd. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, April 20th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy”.

View Our Latest Report on FSNUY

Fresenius SE & Co. Stock Down 2.9%

The business’s fifty day moving average price is $13.27 and its 200 day moving average price is $14.19. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $26.20 billion, a PE ratio of 18.46 and a beta of 0.68.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.28 EPS for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.31%. The business had revenue of $6.94 billion during the quarter. On average, equities research analysts forecast that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.